FOLD
NASDAQAmicus Therapeutics Inc.
News · 26 weeks89-100%
2025-12-142026-06-07
Mix5990d
- Other23(39%)
- SEC Filings22(37%)
- Insider14(24%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.SCHEDULE 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
- SECSEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.SCHEDULE 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
- SECSEC Form 15-12G filed by Amicus Therapeutics Inc.15-12G - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.SCHEDULE 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form EFFECT filed by Amicus Therapeutics Inc.EFFECT - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- INSIDERDirector Wheeler Craig A returned $1,227,150 worth of shares to the company (84,631 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Mcglynn Margaret G returned $1,372,150 worth of shares to the company (94,631 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Whitman Burke W returned $1,719,671 worth of shares to the company (118,598 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Sblendorio Glenn returned $2,067,178 worth of shares to the company (142,564 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Roberts Eiry returned $1,105,988 worth of shares to the company (76,275 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Bleil Lynn Dorsey returned $1,652,144 worth of shares to the company (113,941 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Kelly Michael Aaron returned $1,050,786 worth of shares to the company (72,468 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERDirector Raab Michael returned $1,679,926 worth of shares to the company (115,857 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Accounting Officer Prout Samantha returned $1,826,290 worth of shares to the company (125,951 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Development Officer Castelli Jeff returned $6,192,790 worth of shares to the company (427,089 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Legal Officer Rosenberg Ellen returned $6,944,021 worth of shares to the company (478,898 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief People Officer Clark David Michael returned $3,216,260 worth of shares to the company (221,811 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Financial Officer Harford Simon N.R. returned $2,082,128 worth of shares to the company (143,595 units at $14.50), closing all direct ownership in the company (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
FOLD FAQ
7 questionsWhat does Amicus Therapeutics Inc. do?
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The...Where does FOLD stock trade?
Amicus Therapeutics Inc. (FOLD) is listed on NASDAQ.What sector and industry is FOLD in?
Amicus Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Amicus Therapeutics Inc. go public?
Amicus Therapeutics Inc. (FOLD) completed its IPO in 2007.What are analysts saying about FOLD?
Amicus Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $1450.00 price target on 2026-01-22. Recent price targets range from $1200.00 to $1800.00.What companies are similar to FOLD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FOLD side-by-side with any of them on Quantisnow.How can I track FOLD on Quantisnow?
Quantisnow aggregates Amicus Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FOLD to receive live email and push alerts on every new disclosure.